A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

← catalyst calendar

NCT06321523

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

—

Status

Completed

Study type

Observational

Enrollment

13actual

Sites

Country

South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-03-19

actual

When the study began enrolling

Primary completion

2025-10-13

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-10-13

actual

The whole study's end, after follow-up

First posted

2024-03-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-11-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Transthyretin Amyloid Cardiomyopathy

Intervention

Drug: Tafamidis 61 milligrams

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification